Wells Fargo Sticks to Their Buy Rating for Editas Medicine (EDIT)
National Bank on DRI Healthcare's Casgevy Stream Acquisition
Leerink Partners Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
Sector Update: Health Care Stocks Rise Pre-Bell Friday
Editas Medicine Secures $57M Deal for Gene-Editing Technology
Editas Medicine Reports Sale Of Certain Future License Fees, Other Payments Owed Under Cas9 License Agreement With Vertex To DRI Healthcare Trust Subsidiary For Upfront Cash Payment Of $57M
Editas Medicine Announces $50+ Million Monetization Financing With DRI Healthcare Trust
Express News | Editas Medicine Announces $50+ Million Monetization Financing With Dri Healthcare Trust
Press Release: Editas Medicine Announces $50+ Million Monetization Financing With DRI Healthcare Trust
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
RBC Capital analyst Luca Issi maintains $Editas Medicine(EDIT.US)$ with a hold rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 22.6% and a
Editas Medicine (EDIT) Receives a Hold From RBC Capital
Jones Trading Initiates Coverage On Editas Medicine With Buy Rating, Announces Price Target of $13
JonesTrading Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $13
JonesTrading analyst Soumit Roy initiates coverage on $Editas Medicine(EDIT.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 23.5%
Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough
We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate
Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Editas Medicine Hold Rating With Revised Price Target Amidst Mixed Financial Signals
Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline